Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aptevo Therapeutics Inc. (APVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.9000+0.1300 (+3.45%)
At close: 04:00PM EDT
4.2300 +0.33 (+8.46%)
After hours: 07:44PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close3.7700
Open3.8800
Bid3.8000 x 900
Ask3.9100 x 1300
Day's Range3.8000 - 4.1500
52 Week Range3.0300 - 22.5000
Volume82,649
Avg. Volume97,375
Market Cap19.528M
Beta (5Y Monthly)6.34
PE Ratio (TTM)N/A
EPS (TTM)-5.9980
Earnings DateMay 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for APVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aptevo Therapeutics Inc.
    Technical Assessment: Bearish in the Intermediate-TermCommodities continue to get shellacked, Treasury yields across the curve are still falling, people are starting to suggest that the Federal Reserve won't have to tighten as much as many thought just a month or two ago, recession fears (or worries that we are already in one) are rising quickly, EPS season is almost upon us (with many believing 2022 numbers are far too high), crypto remains in the dumpster, and the horrendous invasion of Ukraine never ends.
    Rating
    Fair Value
    Economic Moat
    19 hours agoArgus Research
View more
Advertisement
Advertisement